- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/24 - Antidepressants
Patent holdings for IPC class A61P 25/24
Total number of patents in this class: 4382
10-year publication summary
|
115
|
164
|
244
|
297
|
313
|
374
|
413
|
481
|
377
|
140
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2703 |
72 |
| Antecip Bioventures II LLC | 325 |
70 |
| Janssen Pharmaceutica N.V. | 3431 |
69 |
| F. Hoffmann-La Roche AG | 7912 |
59 |
| Sage Therapeutics, Inc. | 359 |
58 |
| GH Research Ireland Limited | 59 |
46 |
| Taisho Pharmaceutical Co., Ltd. | 856 |
43 |
| Hoffmann-La Roche Inc. | 3357 |
39 |
| AstraZeneca AB | 2928 |
39 |
| H. Lundbeck A/S | 1203 |
35 |
| Janssen Pharmaceuticals, Inc. | 427 |
32 |
| Intra-Cellular Therapies, Inc. | 407 |
27 |
| Sumitomo Dainippon Pharma Co., Ltd. | 216 |
27 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 818 |
24 |
| Sunshine Lake Pharma Co., Ltd. | 585 |
24 |
| The Regents of the University of California | 19784 |
23 |
| LTS Lohmann Therapie-Systeme AG | 691 |
23 |
| Gilgamesh Pharmaceuticals, Inc. | 56 |
23 |
| Boehringer Ingelheim International GmbH | 4702 |
22 |
| Kyoto University | 2785 |
22 |
| Other owners | 3605 |